Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Oncology Institute (TOI) EBITDA (2020 - 2025)

Oncology Institute (TOI) has disclosed EBITDA for 6 consecutive years, with -$7.0 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EBITDA rose 46.0% year-over-year to -$7.0 million, compared with a TTM value of -$37.1 million through Sep 2025, up 38.54%, and an annual FY2024 reading of -$56.9 million, up 23.23% over the prior year.
  • EBITDA was -$7.0 million for Q3 2025 at Oncology Institute, up from -$10.2 million in the prior quarter.
  • Across five years, EBITDA topped out at -$943000.0 in Q2 2021 and bottomed at -$40.6 million in Q4 2021.
  • Average EBITDA over 5 years is -$14.8 million, with a median of -$14.3 million recorded in 2023.
  • The sharpest move saw EBITDA plummeted 1802.97% in 2022, then skyrocketed 48.43% in 2025.
  • Year by year, EBITDA stood at -$40.6 million in 2021, then surged by 39.32% to -$24.6 million in 2022, then surged by 41.18% to -$14.5 million in 2023, then rose by 24.05% to -$11.0 million in 2024, then skyrocketed by 35.91% to -$7.0 million in 2025.
  • Business Quant data shows EBITDA for TOI at -$7.0 million in Q3 2025, -$10.2 million in Q2 2025, and -$8.9 million in Q1 2025.